In addition to ovarian cancer, deregulation of the mevalonate pathway was already described in various cancers, including prostate, breast, lung, and hepatocellular carcinomas [27], and its main regulator is the Sterol Regulatory Element-Binding Protein 2 (SREBP2). This evidence concerns the gene SREBF2 and ovarian carcinoma.